Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
3,438
Total Claims
$570K
Drug Cost
176
Beneficiaries
$3,241
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 109,535 Physician Assistant providers
-83%
Opioid rate vs peers
1.6% vs 9.2% avg
+351%
Cost per patient vs peers
$3,241 vs $719 avg
+164%
Brand preference vs peers
17.5% vs 6.7% avg
Opioid Prescribing
1.6%
Opioid Rate
54
Opioid Claims
$451
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 594 claims · $509K
Generic: 2,792 claims · $59K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 35 | $46K |
| Sitagliptin Phosphate | 38 | $35K |
| Semaglutide | 22 | $34K |
| Apixaban | 27 | $27K |
| Insulin Glargine,hum.Rec.Anlog | 38 | $25K |
| Linaclotide | 21 | $25K |
| Fluticasone/Umeclidin/Vilanter | 17 | $23K |
| Dapagliflozin Propanediol | 12 | $19K |
| Rivaroxaban | 11 | $19K |
| Insulin Aspart | 20 | $19K |
| Cariprazine Hcl | 12 | $18K |
| Budesonide/Formoterol Fumarate | 18 | $16K |
| Evolocumab | 15 | $8,773 |
| Mirabegron | 17 | $8,096 |
| Empagliflozin/Linagliptin | 12 | $7,616 |
Prescribing Profile
Patient Profile
65
Avg Age
43%
Female
1.11
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About